749269-74-7

Usage

Uses

Used in Organic Chemistry Research:
1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carboxylic acid serves as a valuable compound in organic chemistry research, where it is utilized for the study of cyclopropane-containing compounds and their reactions. Its distinct structural features make it a candidate for exploring novel chemical pathways and mechanisms.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carboxylic acid is used as a building block or intermediate in the synthesis of new drugs. Its bromine and fluorine substituents can be leveraged to modulate the compound's properties, potentially enhancing its pharmacological activity and selectivity.
Used in Drug Synthesis:
1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carboxylic acid is employed as a key intermediate in the synthesis of complex organic molecules, including pharmaceutical agents. Its reactivity and functional groups can be exploited in various synthetic routes to construct diverse drug candidates with potential therapeutic applications.
Used in the Study of Cyclopropane-Containing Compounds:
1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carboxylic acid is utilized in the investigation of cyclopropane-containing compounds, which are known for their unique properties and applications in various fields. Research on 1-(4-BroMo-3-fluorophenyl)cyclopropane-1-carboxylic acid can provide insights into the behavior and potential uses of cyclopropane derivatives in chemistry and medicine.

Upstream product

• 749269-73-6 1-(4-bromo-3-fluorophenyl)cyclopropane-1-carbonitrile 
• 942282-41-9 methyl 2-(4-bromo-3-fluorophenyl)acetate 
• 942282-40-8 2-(4-bromo-3-fluorophenyl)acetic acid 
• 452-74-4 4-bromo-3-fluorotoluene 
• 499983-13-0 2-( 4-bromo-3-fluorophenyl)acetonitrile 
• 127425-73-4 1-bromo-4-(bromomethyl)-2-fluorobenzene 

Downstream Products

• 884905-30-0 1-(3-fluoro-4-iodophenyl)cyclopropanecarboxylic acid 
• 1187369-08-9 [1-(4-bromo-3-fluoro-phenyl)-cyclopropyl]-carbamic acid tert-butyl ester 
• 1268444-93-4 (4R)-1-{[1-(4-bromo-3-fluorophenyl)cyclopropyl]carbonyl}-4-[(2-chlorophenyl)sulfonyl]-N-(1-cyanocyclopropyl)-L-prolinamide 
• 1268445-07-3 (4R)-1-{[1-(4-bromo-3-fluorophenyl)cyclopropyl]carbonyl}-4-{[2-chloro-4-(2,2,2-trifluoroethoxy)phenyl]sulfonyl}-N-(1-cyanocyclopropyl)-L-prolinamide 
• 1403395-87-8 (3-{1-[3-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl]cyclopropyl}-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepin-8-yl)methanol 
• 1403396-91-7 8-({[tert-butyl(dimethyl)silyl]oxy}methyl)-3-{1-[3-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl]cyclopropyl}-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine 
• 1403395-31-2 {3-[1-(3-fluoro-4-pyridin-3-ylphenyl)cyclopropyl]-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepin-8-yl}methanol 
• 1403396-35-9 8-({[tert-butyl(dimethyl)silyl]oxy}methyl)-3-[1-(3-fluoro-4-pyridin-3-ylphenyl)cyclopropyl]-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine 
• 1403395-30-1 {3-[1-(2-fluorobiphenyl-4-yl)cyclopropyl]-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepin-8-yl}methanol 
• 1403396-34-8 3-[1-(4-bromo-3-fluorophenyl)cyclopropyl]-8-({[tert-butyl(dimethyl)silyl]oxy}methyl)-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine 
• 1403396-32-6 1-(4-bromo-3-fluorophenyl)cyclopropanecarbohydrazide 
• 1279100-76-3 1-(2,4'-difluorobiphenyl-4-yl)cyclopropanecarboxylic acid 

Relevant academic research and scientific papers

Inhibitor for AKR1C3 or pharmaceutically acceptable salt of inhibitor as well as preparation method and application of inhibitor or pharmaceutically acceptable salt

The invention discloses an inhibitor for AKR1C3 or a pharmaceutically acceptable salt of the inhibitor as well as a preparation method and application of the inhibitor or the pharmaceutically acceptable salt. Non-steroidal anti-inflammatory drug flurbiprofen is used as a lead compound for structural optimization. The invention discloses the biphenyl-based AKR1C3 inhibitor represented by a formula(I) shown in the specification and the preparation method of the inhibitor. Target activity tests prove that the compounds provided by the invention can significantly inhibit activity of AKR1C3, and can be further used for development of a drug for treating and/or preventing diseases by inhibiting the aldo-keto reductase AKR1C3; and a molecular basis is laid for drug resistance-related mechanisticstudy of tumors.

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

TETRAHYDROTHIAZEPINE DERIVATIVE

The present invention relates to a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof having an excellent effect of inhibiting 11β-hydroxysteroid dehydrogenase type 1: General formula (I) wherein R1 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from substituent group A or a heterocyclic group that may be substituted with 1 to 4 group(s) independently selected from substituent group A; R2 independently represents a halogen atom or a C1-C6 alkyl group; n represents an integer of 0 to 2; and substituent group A represents the group consisting of halogen atoms, C1-C6 alkyl groups, and so forth.

Systematic investigation of halogen bonding in protein-ligand interactions

Halogen bonding triggers activity: Increasing binding affinity was observed for a series of covalent human Cathepsin L inhibitors by exchanging an aryl ring H atom with Cl, Br, and I, which undergo halogen bonding with the C=O group of Gly61 in the S3 pocket of the enzyme. Fluorine, in contrast, strongly avoids halogen bonding (see scheme). The strong distance and angle dependence of halogen bonding was confirmed for biological systems. Copyright

Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates

Poor blood-brain barrier penetration of nonsteroidal anti-inflammatory drugs (NSAIDs) has been blamed for the failure of the selective amyloid lowering agent (SALA) R-flurbiprofen in phase 3 clinical trials for Alzheimer's disease (AD). NO-donor NSAIDs (NO-NSAIDs) provide an alternative, gastric-sparing approach to NSAID SALAs, which may improve bioavailability. NSAID analogues were studied for anti-inflammatory activity and for SALA activity in N2a neuronal cells transfected with human amyloid precursor protein (APP). Flurbiprofen (1) analogues were obtained with enhanced anti-inflammatory and antiamyloidogenic properties compared to 1, however, esterification led to elevated A 1-42 levels. Hybrid nitrate prodrugs possessed superior anti-inflammatory activity and reduced toxicity relative to the parent NSAIDs, including clinical candidate CHF5074. Although hybrid nitrates elevated A 1-42 at higher concentration, SALA activity was observed at low concentrations (1 μM): both A1-42 and the ratio of A 42/A1-40 were lowered. This biphasic SALA activity was attributed to the intact nitrate drug. For several compounds, the selective modulation of amyloidogenesis was tested using an immunoprecipitation MALDI-TOF approach. These data support the development of NO-NSAIDs as an alternative approach toward a clinically useful SALA.

Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of β-amyloid1-42 secretion

Flurbiprofen, a nonsteroidal antiinflammatory drug (NSAID), has been recently described to selectively inhibit β-amyloid1-42 (Aβ42) secretion, the most toxic component of the senile plaques present in the brain of Alzheimer patients. The use of this NSAID in Alzheimer's disease (AD) is hampered by a significant gastrointestinal toxicity associated with cyclooxygenase (COX) inhibition. New flurbiprofen analogues were synthesized, with the aim of increasing Aβ42 inhibitory potency while removing anti-COX activity. In vitro ADME developability parameters were taken into account in order to identify optimized compounds at an early stage of the project. Appropriate substitution patterns at the alpha position of flurbiprofen allowed for the complete removal of anti-COX activity, while modifications at the terminal phenyl ring resulted in increased inhibitory potency on Aβ42 secretion. In rats, some of the compounds appeared to be well absorbed after oral administration and to penetrate into the central nervous system. Studies in a transgenic mice model of AD showed that selected compounds significantly decreased plasma Aβ42 concentrations. These new flurbiprofen analogues represent potential drug candidates to be developed for the treatment of AD.

CATHEPSIN CYSTEINE PROTEASE INHIBITORS

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

1-Phenylalkanecarboxylic acid derivatives, the processes for the preparation thereof and the use thereof in the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease.